Join the 'Plaque Psoriasis' group to help and get support from people like you.
Plaque Psoriasis News
Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Posted 1 day 18 hours ago by Drugs.com
Horsham, Pa., October 13, 2017 ― Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today’s approval marks a significant milestone for this age group as approximately one-third of individuals who develop plaque psoriasis do so before 20 years of age, and there are limited treatment options for adolescents.[1] Since receiving approval in September 2009 for the treatment of adults living with moderate to severe plaque psoriasis, Stelara has become a leading therapeutic option for dermatologists and their patients, with only four doses a year after two starter doses. “Psoriasis can affect many aspects of everyday life and the visible pla ... Read more
Related support groups: Psoriasis, Plaque Psoriasis, Stelara, Ustekinumab
Severe Psoriasis Linked to Higher Risk of Earlier Death
Posted 5 Sep 2017 by Drugs.com
TUESDAY, Sept. 5, 2017 – People with severe cases of the skin disease psoriasis appeared to have almost double the risk of dying during a four-year study than people without the condition, research suggests. But the increased death rate was only seen in those with psoriasis affecting more than 10 percent of their body surface area. For those with less-severe disease, the risk of dying early was actually less than it was for people who didn't have the skin condition. Dr. Robert Kirsner, chair of dermatology at the University of Miami Miller School of Medicine, said that over the last decade or so, doctors have learned that people with psoriasis tend to be less healthy. "They are overweight, have diabetes mellitus, smoke, drink and have high cholesterol," he said. "These factors – as well as the presence of psoriasis itself – increases their risk for vascular disease and other poor ... Read more
Related support groups: Skin Rash, Smoking, Methotrexate, Psoriasis, Smoking Cessation, Plaque Psoriasis, Diabetes Mellitus, Soriatane, Tazorac, Dovonex, Taclonex, Oxsoralen, Acitretin, Calcipotriene, Methoxsalen, Tazarotene, Resorcinol, Vectical, Enstilar, Anthralin
FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Posted 30 Aug 2017 by Drugs.com
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: moderate to severe active rheumatoid arthritis moderate to severe polyarticular juvenile idiopathic arthritis** active psoriatic arthritis active ankylosing spondylitis (an arthritis that affects the spine) moderate to severe active adult Crohn’s disease moderate to severe active ulcerative colitis moderate to severe plaque psoriasis “Cyltezo is the first biosimilar from Boehringer Ingelheim to be approved by the FDA and marks an important step towards our goal of providing new and more affordable treatment options to healthcare providers and patients,” said Ivan Blanarik, Senior Vice President and Head of The ... Read more
Related support groups: Rheumatoid Arthritis, Psoriasis, Humira, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Juvenile Rheumatoid Arthritis, Ulcerative Colitis - Maintenance, Juvenile Idiopathic Arthritis, Humira Pen, Adalimumab, Amjevita, Cyltezo
Janssen Announces FDA Approval of Tremfya (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Posted 17 Jul 2017 by Drugs.com
Horsham, PA, July 13, 2017 ― Janssen Biotech, Inc. (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis. Approval comes after an expedited regulatory review following application of an FDA Priority Review Voucher. Tremfya is administered as a 100 mg subcutaneous injection every eight weeks, following two starter doses at weeks 0 and 4. In clinical studies, patients receiving Tremfya experienced significant improvement in skin clearance and greater improvement in symptoms of plaque psoriasis including itch, pain, stinging, burning and skin tightness when c ... Read more
Related support groups: Psoriasis, Plaque Psoriasis, Tremfya, Guselkumab
Promising Results for Ixekizumab Against Psoriatic Arthritis
Posted 26 May 2017 by Drugs.com
FRIDAY, May 26, 2017 – A new drug might help ease the pain and disability of a form of arthritis often linked to psoriasis. According to Stanford University researchers, psoriatic arthritis is an inflammatory joint disorder tied to an out-of-control immune response. The disease affects about one in every 200 people and is often accompanied by the autoimmune skin disorder psoriasis. Psoriatic arthritis typically arises after the age of 30 and can bring stiffness, pain and swelling of the joints, leading to real disability if treatments don't help. The new study focused on more than 300 adult patients across 10 countries. These patients were no longer seeing an effect from standard biologic drugs or had never experienced a benefit in the first place. That's not uncommon. "Only about half of psoriatic arthritis patients who are given TNF inhibitors get better," study lead author Dr. Mark ... Read more
Related support groups: Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, Taltz, Ixekizumab, Psoriatic Arthropathy
FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade
Posted 27 Apr 2017 by Drugs.com
INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Remicade®i (infliximab), across all eligible indications. In the US, Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and for the treatment of adult plaque psoriasis. Renflexis is the first Samsung Bioepis product approved for marketing in the United States (US). “Since our company was established five years ago, we have strived day in and day out to realize the promise of biosimilars for patients across the United States by offering them treatment options at a lower cost. We hope this regulatory milestone will bring us a step closer to achievin ... Read more
Related support groups: Rheumatoid Arthritis, Crohn's Disease, Psoriatic Arthritis, Remicade, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Renflexis
Health Tip: Caring for Nail Psoriasis
Posted 17 Apr 2017 by Drugs.com
-- Nail psoriasis causes pitting, discoloration and thickening of the nails. So how to take care of your nails if you have the condition? Here are suggestions from the National Psoriasis Foundation: Trim your nails as short as you can, since longer nails are more prone to everyday damage. Protect your nails from injury, which can worsen psoriasis symptoms. When washing dishes, cleaning or cooking, protect your hands with a pair of cotton gloves underneath vinyl or nitrile gloves (not latex). Talk to your doctor about corticosteroid injections and other possible treatments. Read more
Related support groups: Psoriasis, Plaque Psoriasis, Onychomycosis - Fingernail, Psoriatic Arthropathy
Men More Prone to Severe Psoriasis: Study
Posted 7 Apr 2017 by Drugs.com
THURSDAY, April 6, 2017 – Severe psoriasis is much more common in men than women, a new study from Sweden reports. Researchers reviewed data from more than 5,400 people in Sweden with the common skin disease. The study found that women had a significantly lower rate of severe psoriasis than men. This was true for all age groups and for all parts of the body except the head, where severity scores were about the same for both sexes. The discovery that men's psoriasis is often more serious helps explain a gender gap, with more men than women seeking psoriasis treatment, said study senior author Marcus Schmitt-Egenolf. He is a researcher at Umea University's Department of Public Health and Clinical Medicine. "These findings should motivate a gender perspective in the management of severe psoriasis and its comorbidities, such as cardiovascular and metabolic disease," Schmitt-Egenolf said in ... Read more
Related support groups: Psoriasis, Plaque Psoriasis, Psoriatic Arthropathy
FDA Approves Siliq (brodalumab) for Plaque Psoriasis
Posted 2 Mar 2017 by Drugs.com
February 15, 2017 – The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies. "Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today’s approval provides patients with another treatment option for their psoriasis," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. "Patients and their health care providers should discuss the benefits and risks of S ... Read more
Related support groups: Psoriasis, Plaque Psoriasis, Siliq, Brodalumab
Siliq Approved for Plaque Psoriasis
Posted 2 Mar 2017 by Drugs.com
THURSDAY, Feb. 16, 2017 – The injected drug Siliq (brodalumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe plaque psoriasis in adults. Siliq is approved for patients who've already failed to respond to other systemic therapies, the agency noted. The autoimmune disease – so-called because the immune system produces antibodies that attack the body's own tissues – causes thick, scaly patches of red skin. The drug is designed to inhibit the body's inflammatory response that plays a role in the development of plaque psoriasis, the FDA said in a news release. The disease occurs most often in people with a family history, usually between ages 15 and 35. Saliq was evaluated in clinical studies involving more than 4,300 people with moderate-to-severe plaque psoriasis. The most common side effects included joint pain, headache, fatigue, diarrhea, ... Read more
Related support groups: Methotrexate, Psoriasis, Plaque Psoriasis, Soriatane, Tazorac, Dovonex, Taclonex, Oxsoralen, Acitretin, Calcipotriene, Methoxsalen, Tazarotene, Resorcinol, Enstilar, Vectical, Anthralin, Methotrexate LPF Sodium, Avage, Psoriatec, Dritho-Scalp
Immune Disorders Such as MS, Psoriasis May Be Tied to Dementia Risk
Posted 2 Mar 2017 by Drugs.com
WEDNESDAY, March 1, 2017 – People with autoimmune diseases – conditions that cause a person's immune system to turn against the body – appear to have an increased risk of developing dementia, a new British study suggests. Researchers found that 18 out of 25 different autoimmune diseases, such as lupus, psoriasis or multiple sclerosis, "showed a statistically significant association with dementia," said study co-author Dr. Michael Goldacre. He's a professor of public health at the University of Oxford. But Goldacre and other experts stressed that the study didn't prove that autoimmune diseases cause dementia. The research only showed that these conditions are associated with a higher risk of dementia. Specifically, the study found that people with multiple sclerosis appeared to have nearly double the risk of dementia. Psoriasis was associated with a 29 percent increased risk of ... Read more
Related support groups: Multiple Sclerosis, Heart Disease, Ischemic Stroke, Psoriasis, Dementia, Alzheimer's Disease, Transient Ischemic Attack, Plaque Psoriasis, Ischemic Stroke - Prophylaxis, Chronic Spasticity, Spasticity, Ischemic Heart Disease, Psoriatic Arthropathy
Can Depression Up Odds for Arthritis Linked to Psoriasis?
Posted 24 Feb 2017 by Drugs.com
FRIDAY, Feb. 24, 2017 – Depression in people with the chronic inflammatory skin disease psoriasis increases the risk of getting the joint condition known as psoriatic arthritis by about 37 percent, new research indicates. The finding raises concerns because depression is not uncommon in people with psoriasis, according to the authors of the study in the Feb. 22 issue of the Journal of Investigative Dermatology. "For many years, the rheumatology and dermatology communities have been trying to understand which patients with psoriasis go on to develop psoriatic arthritis, and how we might detect it earlier in the disease course," senior investigator Dr. Cheryl Barnabe said in a journal news release. She is from the McCaig Institute for Bone and Joint Health and the O'Brien Institute for Public Health at the University of Calgary in Alberta. While the study found a connection between ... Read more
Related support groups: Depression, Rheumatoid Arthritis, Major Depressive Disorder, Psoriasis, Plaque Psoriasis, Dysthymia, Psoriatic Arthropathy
FDA Approves Injectable Psoriasis Drug for Tough Cases
Posted 16 Feb 2017 by Drugs.com
THURSDAY, Feb. 16, 2017 – A new drug to treat tough cases of the skin condition psoriasis has won approval from the U.S. Food and Drug Administration. Valeant Pharmaceuticals' injectable drug Siliq (brodalumab) was approved for adults with moderate-to-severe psoriasis that isn't responding to other recommended treatments. However, the drug carries a warning about increased risk for suicidal behavior. Psoriasis is characterized by raised patches of red skin and flaking. The condition usually begins between ages 15 and 35 and is thought to be an autoimmune disorder, meaning the body mistakenly attacks healthy cells. "Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today's approval provides patients with another treatment option for their psoriasis," said the FDA's Dr. Julie Beitz. Beitz is director of the Office of Drug ... Read more
Related support groups: Methotrexate, Psoriasis, Plaque Psoriasis, Soriatane, Tazorac, Dovonex, Taclonex, Oxsoralen, Acitretin, Calcipotriene, Methoxsalen, Tazarotene, Resorcinol, Enstilar, Vectical, Anthralin, Methotrexate LPF Sodium, Avage, Psoriatec, Dritho-Scalp
Got an Itch? Use These Tips for Relief -- and Don't Scratch
Posted 31 Jan 2017 by Drugs.com
TUESDAY, Jan. 31, 2017 – Itchy skin is a common problem, but there are several ways to find relief, a dermatologist says. "There are many reasons for itchy skin," Dr. Hassan Galadari said in an American Academy of Dermatology news release. "It could be the result of a skin condition, such as eczema, shingles, hives or psoriasis, or it could be a sign of a contagious disease, like scabies or ringworm." To relieve itchy skin, Galadari offers these tips: Apply a cold, wet cloth or ice pack to the itchy area for five to 10 minutes or until the itch subsides. Or take an oatmeal bath. Use skin moisturizers that contain no additives, fragrances or perfumes. Apply topical anesthetics that contain pramoxine. Apply cooling agents such as menthol or calamine, or refrigerate your moisturizer to help achieve this cooling effect. Avoid scratching. It will irritate your skin and could lead to ... Read more
Related support groups: Skin Rash, Herpes Zoster, Psoriasis, Eczema, Scabies, Plaque Psoriasis, Calamine, Varicella-Zoster, Menthol, Pramoxine, Anusol, Calmoseptine, Biofreeze, Tiger Balm, Analpram-HC, Terocin, Caladryl, Salonpas, Hydrocortisone/Pramoxine, Dendracin
Weight Loss May Ease Psoriasis Symptoms, Study Finds
Posted 5 Jan 2017 by Drugs.com
WEDNESDAY, Jan. 4, 2017 – Could weight loss combat psoriasis? Danish researchers are reporting that obese people with the skin condition who lose 10 percent to 15 percent of their weight may see significant and lasting improvement in their symptoms. The study participants lost an average of 33 pounds over 16 weeks. A year later, those who were still about 22 pounds below their weight from the start of the study maintained their improvements in psoriasis symptoms and quality of life, the study authors said. "Psoriasis is more than just a skin condition," said Dr. Doris Day, a dermatologist at Lenox Hill Hospital in New York City. Increased weight can stress the heart and other organs, and that stress can trigger psoriasis, she said. "We know that weight and psoriasis together and independently increase the risk of high blood pressure and heart disease and diabetes. Psoriasis is an ... Read more
Related support groups: Obesity, Weight Loss, Psoriasis, Plaque Psoriasis, Psoriatic Arthropathy
Ask a Question
Further Information
Related Condition Support Groups
Related Drug Support Groups
Humira, methylprednisolone, Enbrel, Remicade, dexamethasone, Otezla, hydroxyurea, Cosentyx, Dovonex, view more... infliximab, adalimumab, Taclonex, Taltz, etanercept, calcipotriene, secukinumab, apremilast, Inflectra, Enstilar, Tremfya, Renflexis, Siliq, Amjevita, Erelzi, Cyltezo, ixekizumab, Taclonex Scalp, Amevive, Calcitrene, betamethasone / calcipotriene, Sernivo, Dovobet, efalizumab, alefacept, Raptiva, guselkumab, brodalumab, Sorilux
